-
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
Teh, C. E., Peng, H., Luo, M-X., Tan, T., Trussart, M., Howson, L. J., Chua, C. C., Muttiah, C., Brown, F., Ritchie, M. E., Wei, A. H., Roberts, A. W., Bryant, V. L., Anderson, M. A., Lindeman, G. J., Huang, D. C. S., Thijssen, R. & Gray, D. H. D., 1 Jun 2023, In: Blood advances. 7, 12, p. 2733-2745 13 p.Research output: Contribution to journal › Article › Academic › peer-review
-
JAK–STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL
Haselager, M. V., Thijssen, R., Bax, D., Both, D., de Boer, F., Mackay, S., Dubois, J., Mellink, C., Kater, A. P. & Eldering, E., Jun 2023, In: Molecular Oncology. 17, 6, p. 1112-1128 17 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
Thijssen, R., Tian, L., Anderson, M. A., Flensburg, C., Jarratt, A., Garnham, A. L., Jabbari, J. S., Peng, H., Lew, T. E., Teh, C. E., Gouil, Q., Georgiou, A., Tan, T., Djajawi, T. M., Tam, C. S., Seymour, J. F., Blombery, P., Gray, D. H. D., Majewski, I. J., Ritchie, M. E., & 2 others , 17 Nov 2022, In: Blood. 140, 20, p. 2127-2141 15 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications